Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Posters

48P - Low glucose sensitizes A431 skin cancer cells to metformin treatments: A way forward to targeting PD-L1

Date

06 Oct 2021

Session

e-Posters

Presenters

Alexandra Mikhaylova

Citation

Annals of Oncology (2021) 32 (suppl_6): S1345-S1371. 10.1016/annonc/annonc740

Authors

A.L. Mikhaylova1, A.A. Basharina2, D.V. Sorokin3, G.I. Buravchenko4, S.A. Samsonik2, T.A. Bogush2, A.M. Scherbakov3

Author affiliations

  • 1 N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation, Moscow/RU
  • 2 N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation, 115522 - Moscow/RU
  • 3 N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia, 115522 - Moscow/RU
  • 4 Gause Institute of New Antibiotics, 119021 - Moscow/RU
More

Abstract 48P

Background

In several drug repurposing trials, metformin has shown promising effects against various cancers. Metformin, a complex I inhibitor, actively regulates the metabolism of tumor cells through LKB/AMPK, Akt and mTOR pathways. This work aims to investigate the antiproliferative effects of metformin on A431 cells and to evaluate its activities as a possible anti-PD-L1 adjuvant.

Methods

Epidermoid carcinoma cell culture A-431 (ATCC, USA) was incubated with metformin (15 mM) in a high (4.5 g/L) and low (1.0 g/L) glucose growth medium. The antiproliferative activity of metformin was assessed by the MTT test. Expression of PD-L1 was evaluated quantitatively by immunofluorescent assay and flow cytometry. The primary anti-PD-L1 (ARG65862) and secondary (DyLight650, ab98729) antibodies were used. Two indexes of PD-L1 expression were calculated: level is the ratio (%) of specifically fluorescent cells to the control (incubation with the secondary antibody only) and intensity is the ratio of mean fluorescence intensity in the experimental sample to the control.

Results

Metformin has shown significant antiproliferative effects on A431 cells. A high level of the phosphorylated form of AMPK (p-AMPK), one of the metformin targets, was found in A431 cells. Metformin treatment did not increase p-AMPK but significantly reduced the expression of cyclin D1, a key regulator of the cell cycle, and also blocked the expression of glucose transporter GLUT1. Low glucose significantly enhanced metformin effects on GLUT1 expression. In untreated A431 cells, there was no difference in both the level and intensity of PD-L1 expression between high vs low glucose growth medium. In the high glucose growth medium, 24h or 72h metformin treatment did not alter PD-L1 expression. In the low glucose growth medium, metformin treatment of A431 cells for 24h and 72h decreased the PD-L1 expression: the level – in 1.4 and 1.6 times; intensity of the marker expression – in 1.3 and 1.7 times, respectively.

Conclusions

Metformin exhibits pronounced antiproliferative effects against skin cancer cells, including through blocking the cell cycle and glucose transporter GLUT1. Low glucose enhances the action of metformin as a potential adjuvant to anti-PD-L1 therapy.

Legal entity responsible for the study

The authors.

Funding

The Ministry of Health of Russian Federation (grant “Development and assessment of the clinical significance of a new technology for the molecular prediction of the resistance and aggressiveness of solid epithelial neoplasms”, #AAAA-A20-120020690077-0, immunofluorescent assays and flow cytometry) and the Russian Science Foundation (agreement #20-13-00402, in vitro experiments with A431 cells).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.